GTS Securities’s Krystal Biotech KRYS Stock Holding History

GTS Securities’s Portfolio KRYS Stock Details KRYS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-1,108	Closed	-$286K	–	1654
2026 Q1	$286K	Buy	+1,108	New	+$295K	0.01%	1133

Other funds holding KRYS

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

GTS Securities's KRYS Position: Q2 2026 in Review

GTS Securities sold out of Krystal Biotech (KRYS) in Q2 2026, closing a stake of 1,108 shares — an estimated $286K sold.

GTS Securities first reported a position in KRYS in Q1 2026 and held it in 1 quarter. The position peaked at $286K in Q1 2026. 423 funds tracked by Wall St. Rank hold KRYS as of Q2 2026.

GTS Securities reported no remaining Krystal Biotech position as of Q2 2026 after selling out during the quarter.
GTS Securities sold 1,108 Krystal Biotech shares in Q2 2026, an estimated $286K.
GTS Securities first reported a position in Krystal Biotech in Q1 2026 and held it in 1 quarter.
GTS Securities's Krystal Biotech position peaked at $286K in Q1 2026.
423 funds tracked by Wall St. Rank held Krystal Biotech as of Q2 2026.

Based on GTS Securities's 13F filing for Q2 2026, filed 14 Aug 2026.